No Data
Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?
We Think Prime Medicine (NASDAQ:PRME) Needs To Drive Business Growth Carefully
Express News | Prime Medicine Inc Files for Resale of up to 11 Mln Common Shares by the Selling Stockholder - SEC Filing
JMP Securities Initiates Prime Medicine at Market Outperform With $10 Price Target
JMP Securities Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $10
Prime Medicine, Inc.: Innovative Gene Editing Platform With Significant Market Potential
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
J L 7 2 : Master, hello. In your opinion, is this a good thing or a bad thing?
Trytosaveabit OP J L 7 2 : Good!
J L 7 2 Trytosaveabit OP : Thank you for your reply, I still hold a portion
Trytosaveabit OP J L 7 2 : You’re welcome! GL and big profits to ya
J L 7 2 Trytosaveabit OP : 大家一样都赚大钱
